Scisparc Ltd SPRC

$3.63 -0.31 (-7.87%)

Valuation

Market cap
2,228,000
Revenue TTM
$860,000
Net income TTM
$-12,180,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,416.28%
Debt to equity
0.24

Trading

Volume
12,400
Avg volume
44,194
Day's range
$3.59 – $3.73
Shares out
566,000
Stochastic %K
3%
Beta
2.83
Analysts
Strong Buy
Price target
$20.00

Price

Company profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and o...

Show more

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 7 334 47180
Website
https://scisparc.com
Address
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv-Yafo, Israel

Latest news

Stocktwits

topstockalerts Oct 15, 3:16 PM
$SPRC the trend keeps tightening up
0 replies
StocksReportsX Oct 15, 3:13 PM
Watchlist update: $DRMA cleared $0.81 and both $0.85/$0.90 targets. $SPRC passed its $5.05 first target before reversing. $IBRX tested the $10.50 area, then faded. $OPK hasn’t crossed $1.73 since the post. $DRMA has shown the strongest follow-through of these four.
0 replies
SPIKY2026 Oct 15, 3:01 PM
$SPY $SPRC needs a spiky
0 replies
SPIKY2026 Oct 15, 2:56 PM
$SPRC 450 target $SPY
0 replies
SPIKY2026 Oct 15, 2:50 PM
$SPRC $SPY Double bottom?
0 replies
SPIKY2026 Oct 15, 2:49 PM
$SPRC $SPY im in again
0 replies
BULLNATION_ Oct 15, 2:48 PM
$BKYI Who is saying it? Well the guys that called $100+ on SDOT at $16 and SMX at $4 and it reached $400+ Get your baggage and hold tight! $SPRC $DRMA $WETO
1 replies
SmartMoneyTradez Oct 15, 2:47 PM
$AMOD They cannot short this period. US stock and low float (Float & OS:2.36M / 57.52M) Short Interest Ratio 0.73 Days to Cover, Short Interest % Float 6.53 , Off-Exchange Short Volume 24,800 Shares . Easy 4$ here $SPRC $DRMA $SDST $NCPL
0 replies